Mankind Pharma has witnessed a decline in its stock prices, dropping more than 2% as investors await the company’s second-quarter (Q2) results. The stock opened at ₹2,730.00, with a high of ₹2,730.00 and a low of ₹2,652.20 during the trading session.
The company’s stock performance has been volatile, with a 52-week high of ₹2,835.00 and a low of ₹1,733.00, reflecting the challenges and opportunities in the pharmaceutical sector.
This decline may present a buying opportunity for investors looking to capitalize on potential market recovery following the earnings announcement.
As of 10:46 am, Mankind Pharma shares were trading 2.44% lower at Rs 2,664.65 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
